Mònica Angerri

Non-Criteria Obstetric Antiphospholipid Syndrome: Myth or Reality?

NC-OAPS: heterogeneous condition and ambiguously described in literature

#APS #OAPS #Pregnancy #autoimmune

Behçet syndrome

🩸systemic #vasculitis, affects vessels of all calibers
🩺 venous #thrombosis with arterial #aneurysms, inflammatory parenchymal brain involvement, posterior #uveitis with retinal vasculitis, bipolar #ulcers and erythema nodosum
⁉️ controversy: pathergy test or HLA-B*51 in diagnosis

Arterial and venous thrombosis in systemic and monogenic vasculitis - Nature Reviews Rheumatology Systemic vasculitis, including monogenic forms, is associated with an increased risk of arterial and venous thromboembolic events (AVTEs). This Review highlights the latest advances in the understandi...

Arterial and venous thrombosis in systemic and monogenic vasculitis

⚠️ Be aware for early diagnosis‼️

🧬 Genetic testing vital—variable penetrance! Early strokes hint at diagnosis.

#vasculitis #thrombosis #monogenic #stroke #skin

www.nature.com/articles/s41...

EULAR recommendations for use of antirheumatic
drugs in reproduction, pregnancy, and lactation: 2024
update

🤰🏽👩🏽‍🍼

ard.eular.org/action/showP...

Remnant cholesterol predicts risk
of recurrent thrombosis beyond LDL‑cholesterol
in patients with antiphospholipid syndrome

🟠RC ➡️ increased risk of trombosis
🟠RC marker for thrombotic risk❓
🟠potential target
for therapeutic intervention.

bmcmedicine.biomedcentral.com/counter/pdf/...

Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project ABSTRACTObjectives. The lack of uniform terminology and abbreviations for anti-synthetase syndrome has led to significant challenges in research and clinic

Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project

🚩lack of uniform terminology and abbreviations = challenges in research and clinical practice
🏳️anti-synthetase syndrome and ASyS should be adopted as the standard nomenclature
academic.oup.com/rheumatology...

🚨2024 American College of Rheumatology (ACR)
Guideline for the Screening, Treatment, and
Management of Lupus Nephritis

#Lupus #Nephritis #Guideline #Treatment #SLE

assets.contentstack.io/v3/assets/bl...

💕

To B or Not to B — the Role of B-Cell Depletion in Lupus Nephritis | NEJM B cells play a key role in the pathogenesis of lupus nephritis, yet in the Lupus Nephritis Assessment with Rituximab (LUNAR) trial, rituximab therapy did not improve clinical outcomes after 1 year ...

To B or Not to B — the Role of B-Cell Depletion in Lupus Nephritis

www.nejm.org/doi/full/10....

Recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease: A scoping review Objective Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease-modifying anti-rh...

Recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease: A scoping review

acrjournals.onlinelibrary.wiley.com/doi/10.1002/...

A proposed clinical tool to identify high-risk patients for monogenic lupus: a pilot study Paediatric Rheumatology; Authors: S.M. Al-Mayouf, D. Hadef, N. Aljaberi, N. Movahedi, A. Aleed, A. Almutairi, A. Asiri, S. Volpi, M. Gattorno, C.-Y. Wu, H. Tamim, A. Al-Saleem

A proposed clinical tool to identify high-risk patients for #monogenic #lupus: a pilot study

💡<5 years
💡cosanguinity
💡Family #SLE
💡elevated ANA
💡pancytopenia
💡cutaneus lesions
💡Low C1q
💡Recurrent infections
💡Failure to thrive

www.clinexprheumatol.org/abstract.asp...

IL-10 in Systemic Lupus Erythematosus: Balancing Immunoregulation and Autoimmunity

🔑involved in inflammatory and immune processes in SLE.
🔹IL-10 did not correlate with disease activity, organ in-
volvement, or treatment response.

www.mdpi.com/1422-0067/26...

Prognostic insights from symptom clustering analysis in systemic lupus erythematosus Objective Systemic lupus erythematosus (SLE), a systemic autoimmune disease with heterogeneous severity, poses a challenge in classifying patients due to its dynamic phenotype. We therefore aimed to i...

Prognostic insights from symptom clustering analysis in systemic lupus erythematosus

1️⃣ Articular/mucocutaneous ➡️better survival
2️⃣Severe phenotype with renal involvement ➡️ poor prognosis
3️⃣Mixed connective tissue disease-like features with anti-U1-RNP antibodies

rmdopen.bmj.com/content/11/2...

British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024 The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of Behçets. The document aims to offer a

British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2024

👇🏼👀

academic.oup.com/bjd/article/...

Therapeutic approaches for
#SAPHO syndrome from the
perspective of pathogenesis:
a review of the literature

🔸Autoinflammatory
🔸cutaneous & osteoarticular
🔹ATB, tonsillectomy
🔹DMARDs
🔹Bisphosphonates

www.frontiersin.org/journals/imm...

Autoinflammatory Diseases: A Review Autoinflammatory disease (AID) is a vast spectrum of disorders characterized by recurrent attacks of sterile inflammation. Since the first cloning of the familial Mediterranean fever gene in 1997, the...

Autoinflammatory Diseases: A Revision

www.jrheum.org/content/51/9...

Urine Protein Tests in Systemic Lupus Erythematosus:
What Do They Mean?

#SLE #Lupus #LN

www.jrheum.org/content/jrhe...

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis | NEJM Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several...

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

📌In patients with giant-cell arteritis, upadacitinib at a dose of 15 mg — but not 7.5 mg — with a 26-week glucocorticoid taper showed efficacy superior to that of placebo with a 52-week glucocorticoid taper

www.nejm.org/doi/full/10....

Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis Objectives The RESOLVE-1 trial of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc) allowed background immunosuppressive therapy (IST) at the discretion of individual investigators, and no s...

Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis

🔸MMF in dcSSc and show benefit especially in early-stage disease. 🔸High-risk ab for lung fibrosis ➡️ suitable for MMF treatment.

acrjournals.onlinelibrary.wiley.com/doi/full/10....

Familial Mediterranean Fever; Recent Advances, Future Prospectives

🤩 Wonderful review of #FMF, it’s a must!

www.mdpi.com/2075-4418/15...

2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis The accepted version of this article was posted prematurely on March 24, 2025. The final version of record will be made fully available at a later date.

2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

acrjournals.onlinelibrary.wiley.com/doi/10.1002/...

Thoracic Manifestations of ANCA-associated Vasculitis: Review of the 2022 American College of Rheumatology–European Alliance of Associations of Rheumatology Classification Criteria

#ANCA #Vasculitis

pubs.rsna.org/doi/10.1148/...

Systemic lupus erythematosus: one year in review 2025

🔸New insights into immune dysregulation
🔸Emerging treatments: Promising therapies
🔸Real-world impact: Anifrolumab and belimumab

www.clinexprheumatol.org/article.asp?...

Just Autoimmunity? The Role of the Innate Immune Response... : JCR: Journal of Clinical Rheumatology ith conventional or biologic drugs. However, in some cases, the clinical response is limited and frequently takes a high toll of toxicity in patients. The last 2 decades have brought up novel discover...

Just Autoimmunity? The Role of the Innate Immune Response in Lupus

#Lupus #SLE #Autoimmunity

journals.lww.com/jclinrheum/f...

👀

Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

academic.oup.com/rheumatology...

Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus Introduction Physical activity (PA) holds a pivotal role in the improvement of mental health or depressive symptoms, as well as in the prevention of cardiovascular diseases (CVDs). Patients with SLE a...

Levels of physical activity in a large international cohort of patients with systemic lupus erythematosus

👏🏻 inverse association between physical activity levels and fatigue, pain, stress or depression

PRESCRIBE EXERCISE TO YOUR PATIENTS🫶🏼

lupus.bmj.com/content/12/1...

Recent advances in the diagnosis and management of neuropsychiatric lupus - Nature Reviews Rheumatology Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) are common and negatively impact health. Diagnosing neuropsychiatric SLE is challenging owing to a lack of reliable biomarkers, an...

Recent advances in the diagnosis and management of neuropsychiatric lupus

www.nature.com/articles/s41...

Diagnostic, research, and real-life effect of the 2023 EULAR−ACR classification criteria for antiphospholipid syndrome The role of classification criteria is particularly important in rheumatic diseases compared with other medical disorders, as the complexity and overlapping symptoms of these conditions make diagnosis...

Diagnostic, research, and real-life effect of the 2023 EULAR−ACR classification criteria for antiphospholipid syndrome

#APL #antiphospholipid

www.thelancet.com/journals/lan...

Evolution and trajectory of B-cell targeted therapies in rheumatic diseases Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse autoimmune rheumatic diseases. B cells remain the only cell type to be specificall...

Evolution and trajectory of B-cell targeted therapies in rheumatic diseases

‼️20 years of clinical and translational insights drawn from B-cell targeted therapies for autoimmune diseases.

www.thelancet.com/journals/lan...